---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-033604"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:34:58.298309+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Puma raises 2025 guidance; Q3 GAAP net income $8.8M vs $20.3M YoY on lower royalty revenue

## Summary
- Q3 GAAP net income $8.8M ($0.17 diluted) vs $20.3M ($0.41) YoY; non-GAAP adj. net income $10.5M ($0.21) vs $22.4M ($0.46).
- Q3 product revenue $51.9M (vs $56.1M); total revenue $54.5M (vs $80.5M) driven by lower royalty from China licensee.
- Updated FY2025 guidance: product revenue $198-200M, total revenue $220-223M, net income $27-29M (all raised from prior).
- Cash & securities $94.4M at Sep 30, 2025; operating cash flow $9.7M in Q3.
- Interim data from ALISCA-Breast1 and ALISCA-Lung1 alisertib trials expected H1 2026.

## SEC filing metadata
- accession: 0001437749-25-033604
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/0001437749-25-033604-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/pbyi20250901_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-033604
- JSON: https://secwatch.observer/filing/0001437749-25-033604.json
- Plain text: https://secwatch.observer/filing/0001437749-25-033604.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.